Top 5 High-Yield S&P 500 Stocks to Buy for Reliable Returns in 2026Zacks Investment Research • 12/23/25
J&J ordered to pay record $1.5B in talc cancer lawsuit — while vowing to appeal ‘unconstitutional' rulingNew York Post • 12/23/25
J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant (Revised)Zacks Investment Research • 12/23/25
Over $1.5 Billion Baltimore Verdict Holds Johnson & Johnson Liable Over Iconic Baby PowderBusiness Wire • 12/23/25
J&J Stock Trading Above 50- & 200-Day SMA for 6 Months: How to PlayZacks Investment Research • 12/22/25
Minnesota jury says Johnson & Johnson owes $65.5 million to woman with cancer who used talcum powderNew York Post • 12/20/25
Minnesota Jury Delivers $65.5 Million History-Making Verdict Against Johnson & JohnsonBusiness Wire • 12/19/25
J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug RybrevantZacks Investment Research • 12/18/25
Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural HematomaPRNewsWire • 12/18/25
Johnson & Johnson: Valuation Premium Justified By Accelerating Growth And Mix PremiumizationSeeking Alpha • 12/18/25
U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)PRNewsWire • 12/17/25
Take the Zacks Approach to Beat the Markets: Liquidia, Western Digital & Johnson & Johnson in FocusZacks Investment Research • 12/15/25
Forget the 2.8% Social Security Increase. These Aristocrats Pay You 4% to 7% More Annually24/7 Wall Street • 12/14/25
California Jury Awards $40 Million in Landmark Talc Verdict Against Johnson & JohnsonBusiness Wire • 12/14/25